参考文献/References:
[1] McDonagh TA,Metra M,Adamo M,et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure[J]. Eur Heart J,2021,42(36):3599-3726.
[2] Roger VL. Epidemiology of heart failure:a contemporary perspective[J]. Circ Res,2021,128(10):1421-1434.
[3] Heidenreich PA,Bozkurt B,Aguilar D,et al. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure:Executive Summary:A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines[J]. J Am Coll Cardiol,2022,79(17):1757-1780.
[4] Amdani S,Conway J,George K,et al. American Heart Association Council on Lifelong Congenital Heart Disease and Heart Health in the Young; Council on Arteriosclerosis,Thrombosis and Vascular Biology;Council on Cardiovascular Surgery and Anesthesia; and Council on Cardiovascular and Stroke Nursing. evaluation and management of chronic heart failure in children and adolescents with congenital heart disease:A Scientific Statement From the American Heart Association[J]. Circulation,2024,150(2):e33-e50.
[5] Njoroge JN,Teerlink JR. Pathophysiology and therapeutic approaches to acute decompensated heart failure[J]. Circ Res,2021,128(10):1468-1486.
[6] Heidenreich PA,Bozkurt B,Aguilar D,et al. 2022 AHA/ACC/HFSA Guideline for the management of heart failure:a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines[J]. Circulation,2022,145(18):e895-e1032.
[7] Xie SY,Liu SQ,Zhang T,et al. USP28 Serves as a key suppressor of mitochondrial morphofunctional defects and cardiac dysfunction in the diabetic heart[J]. Circulation,2024,149(9):684-706.
[8] Cluntun AA,Badolia R,Lettlova S,et al. The pyruvate-lactate axis modulates cardiac hypertrophy and heart failure[J]. Cell Metab,2021,33(3):629-648.e10.
[9] Hinton A Jr,Claypool SM,Neikirk K,et al. Mitochondrial structure and function in human heart failure[J]. Circ Res,2024,135(2):372-396.
[10] Chen Y,Yuan C,Qin W,et al. TMAO promotes vascular endothelial cell pyroptosis via the LPEAT-mitophagy pathway[J]. Biochem Biophys Res Commun,2024,703:149667.
[11] Valero-Mu?oz M,Oh A,Faudoa E,et al. Endothelial-Mesenchymal transition in heart failure with a preserved ejection fraction:insights into the cardiorenal syndrome[J]. Circ Heart Fail,2021,14(9):e008372.
[12] An X,Ma X,Liu H,et al. Inhibition of PDGFRβ alleviates endothelial cell apoptotic injury caused by DRP-1 overexpression and mitochondria fusion failure after mitophagy[J]. Cell Death Dis,2023,14(11):756.
[13] Raffa S,Forte M,Gallo G,et al. Atrial natriuretic peptide stimulates autophagy/mitophagy and improves mitochondrial function in chronic heart failure[J]. Cell Mol Life Sci,2023,80(5):134.
[14] Lv Y,Yu Z,Zhang P,et al. The structure and function of FUN14 domain-containing protein 1 and its contribution to cardioprotection by mediating mitophagy. Front Pharmacol[J]. 2024,15:1389953.
[15] Scandalis L,Kitzman DW,Nicklas BJ,et al. Skeletal Muscle Mitochondrial Respiration and Exercise Intolerance in Patients With Heart Failure With Preserved Ejection Fraction[J]. JAMA Cardiol,2023,8(6):575-584.
[16] Liu M,Zhai L,Yang Z,et al. Integrative proteomic analysis reveals the cytoskeleton regulation and mitophagy difference between ischemic cardiomyopathy and dilated cardiomyopathy[J]. Mol Cell Proteomics,2023,22(12):100667.
[17] Rawnsley DR,Islam M,Zhao C,et al. Mitophagy facilitates cytosolic proteostasis to preserve cardiac function[J]. bioRxiv [Preprint],2024,2024.11.24.624947.doi: 10.1101/2024.11.24.624947.
[18] Tripathi M,Singh BK,Zhou J,et al. Vitamin B12 and folate decrease inflammation and fibrosis in NASH by preventing syntaxin 17 homocysteinylation[J]. J Hepatol,2022,77(5):1246-1255.
[19] Wang Q,Su H,Liu J. Protective effect of natural medicinal plants on cardiomyocyte injury in heart failure:targeting the dysregulation of mitochondrial homeostasis and mitophagy[J]. Oxid Med Cell Longev,2022,2022:3617086.
[20] Zhang Q,Siyuan Z,Xing C,et al. SIRT3 regulates mitochondrial function:a promising star target for cardiovascular disease therapy [J]. Biomed Pharmacother,2024,170:116004.
[21] Hu J,Liu T,Fu F,et al. Omentin1 ameliorates myocardial ischemia-induced heart failure via SIRT3/FOXO3a-dependent mitochondrial dynamical homeostasis and mitophagy[J]. J Transl Med,2022,20(1):447.
[22] Zhou JC,Jin CC,Wei XL,et al. Mesaconine alleviates doxorubicin-triggered cardiotoxicity and heart failure by activating PINK1-dependent cardiac mitophagy[J]. Front Pharmacol,2023,14:1118017.
[23] Cai C,Li Z,Zheng Z,et al. Pgam5-mediated PHB2 dephosphorylation contributes to endotoxemia-induced myocardial dysfunction by inhibiting mitophagy and the mitochondrial unfolded protein response[J]. Int J Biol Sci,2023,19(14):4657-4671.
[24] Song Y,Zhang Q,Ban R,et al. Single-nucleus RNA sequencing reveals that macrophages and smooth muscle cells promote carotid atherosclerosis progression through mitochondrial autophagy[J]. Medicine (Baltimore),2024,103(7):e37171.
[25] Liu Y,Huang Y,Xu C,et al. Mitochondrial dysfunction and therapeutic perspectives in cardiovascular diseases[J]. Int J Mol Sci,2022,23(24):16053.
[26] Xu H,Wang X,Yu W,et al. Syntaxin 17 protects against heart failure through recruitment of CDK1 to promote DRP1-Dependent mitophagy[J]. JACC Basic Transl Sci,2023,8(9):1215-1239.
[27] Coluccia R,Raffa S,Ranieri D,et al. Chronic heart failure is characterized by altered mitochondrial function and structure in circulating leucocytes[J]. Oncotarget,2018,9(80):35028-35040.
[28] Deng Z,Yao J,Xiao N,et al. DNA methyltransferase 1 (DNMT1) suppresses mitophagy and aggravates heart failure via the microRNA-152-3p/ETS1/RhoH axis[J]. Lab Invest,2022,102(8):782-793.
[29] Xiong R,Li N,Chen L,et al. STING protects against cardiac dysfunction and remodelling by blocking autophagy[J]. Cell Commun Signal,2021,19(1):109.
[30] Nah J,Shirakabe A,Mukai R,et al. Ulk1-dependent alternative mitophagy plays a protective role during pressure overload in the heart[J]. Cardiovasc Res,2022,118(12):2638-2651.
[31] Wang B,Nie J,Wu L,et al. AMPKα2 protects against the development of heart failure by enhancing mitophagy via PINK1 phosphorylation[J]. Circ Res,2018,122(5):712-729.
[32] Bozkurt B,Fonarow GC,Goldberg LR,et al. ACC’s heart failure and transplant section and leadership council. cardiac rehabilitation for patients with heart failure:JACC Expert Panel[J]. J Am Coll Cardiol,2021,77(11):1454-1469.
[33] Guan Z,Chen J,Wang L,et al. Nuanxinkang prevents the development of myocardial infarction-induced chronic heart failure by promoting PINK1/Parkin-mediated mitophagy[J]. Phytomedicine,2023,108:154494.
[34] Picca A,Calvani R,Coelho-Júnior HJ,et al. Mitophagy:at the heart of mitochondrial quality control in cardiac aging and frailty[J]. Exp Gerontol,2021,153:111508.
[35] Moturi S,Ghosh-Choudhary SK,Finkel T. Cardiovascular disease and the biology of aging[J]. J Mol Cell Cardiol,2022,167:109-117.
[36] Nishiji T,Hoshino A,Uchio Y,et al. Generation of inducible mitophagy mice[J]. Genes Cells,2024,29(2):159-168.
[37] Zhuang H,Li C,Wang L,et al. High-Throughput screening of an FDA-Approved compound library reveals a novel GAS6 receptor agonist for therapeutic intervention in septic myocardial and microvascular injury via modulation of danger-associated molecular patterns[J]. Int J Biol Sci,2024,20(15):6222-6240.
[38] Stotland AB,Spivia W,Orosco A,et al. MitoPlex:a targeted multiple reaction monitoring assay for quantification of a curated set of mitochondrial proteins[J]. J Mol Cell Cardiol,2020,142:1-13.
[39] Shao M,Li L,Ma L,et al. Activation of RXRαexerts cardioprotection through transcriptional upregulation of Ndufs4 in heart failure[J]. Sci Bull (Beijing),2024,69(9):1202-1207.
[40] Peng F,Liao M,Jin W,et al. 2-APQC,a small-molecule activator of Sirtuin-3 (SIRT3),alleviates myocardial hypertrophy and fibrosis by regulating mitochondrial homeostasis[J]. Signal Transduct Target Ther,2024,9(1):133.
[41] Fu J,Su C,Ge Y,et al. PDE4D inhibition ameliorates cardiac hypertrophy and heart failure by activating mitophagy[J]. Redox Biol,2025,81:103563.
[42] Nollet EE,Duursma I,Rozenbaum A,et al. Mitochondrial dysfunction in human hypertrophic cardiomyopathy is linked to cardiomyocyte architecture disruption and corrected by improving NADH-driven mitochondrial respiration[J]. Eur Heart J,2023,44(13):1170-1185.
[43] Raizner AE,Qui?ones MA. Coenzyme Q10 for patients with cardiovascular disease:JACC focus seminar[J]. J Am Coll Cardiol,2021,77(5):609-619.
[44] Palomer X,Román-Azcona MS,Pizarro-Delgado J,et al. SIRT3-mediated inhibition of FOS through histone H3 deacetylation prevents cardiac fibrosis and inflammation[J]. Signal Transduct Target Ther,2020,5(1):14.
[45] Forte M,D’Ambrosio L,Schiattarella GG,et al. Mitophagy modulation for the treatment of cardiovascular diseases[J]. Eur J Clin Invest,2024,54(8):e14199.
[46] Svagusa T,Sikiric S,Milavic M,et al. Heart failure in patients is associated with downregulation of mitochondrial quality control genes[J]. Eur J Clin Invest,2023,53(11):e14054.
[47] Han X,Ashraf M,Shi H,et al. Combined endurance and resistance exercise mitigates age-associated cardiac dysfunction[J]. Adv Biol (Weinh),2025,9(6):e2400137.
[48] Peng L,Li S,Cai H,et al. Ginsenoside Rg1 treats chronic heart failure by downregulating ERK1/2 protein phosphorylation[J]. In Vitro Cell Dev Biol Anim,2024,60(9):1085-1098.
[49] Luo Y,Li Y,He L,et al. Xinyang tablet ameliorates sepsis-induced myocardial dysfunction by regulating Beclin-1 to mediate macrophage autophagy and M2 polarization through LncSICRNT1 targeting E3 ubiquitin ligase TRAF6[J]. Chin Med. 2023,18(1):143.
[50] Ko CY,Lin YY,Achudhan D,et al. Omentin-1 ameliorates the progress of osteoarthritis by promoting IL-4-dependent anti-inflammatory responses and M2 macrophage polarization[J]. Int J Biol Sci,2023,19(16):5275-5289.
[51] Gwon JG,Lee SM. Role of PTEN-Induced protein kinase 1 as a mitochondrial dysfunction regulator in cardiovascular disease pathogenesis[J]. Vasc Specialist Int,2024,40:9.
相似文献/References:
[1]戴玫,付珞,胡建英,等.慢性心力衰竭患者应用高强度间歇性有氧训练研究进展[J].心血管病学进展,2016,(3):271.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.014]
DAI Mei,FU Luo,HU Jianying,et al.Advances in Research on High-intensity Interval Training in Chronic Heart Failure[J].Advances in Cardiovascular Diseases,2016,(9):271.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.014]
[2]张培,综述,刘剑,等.慢性心力衰竭并发肌少症的研究进展[J].心血管病学进展,2016,(3):275.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.015]
ZHANG Pei,LIU Jian.Research Progress in Chronic Heart Failure-induced Sarcopenia[J].Advances in Cardiovascular Diseases,2016,(9):275.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.015]
[3]田晶,张青,张岩波,等.慢性心力衰竭结局评价指标研究进展[J].心血管病学进展,2019,(6):931.[doi:10.16806/j.cnki.issn.1004-3934.2019.0.023]
TIAN Jing,ZHANG qing,ZHANG Yanbo,et al.Outcome Indicators for Chronic Heart Failure[J].Advances in Cardiovascular Diseases,2019,(9):931.[doi:10.16806/j.cnki.issn.1004-3934.2019.0.023]
[4]胡威,苏芳菊,张卫泽.左室四极导线在心脏再同步化治疗中的应用进展[J].心血管病学进展,2020,(3):268.[doi:10.16806/j.cnki.issn.1004-3934.2020.03.013]
HU Wei,SU Fangju,ZHANG Weize.Application of Left Ventricular Quadrupole in Cardiac Resynchronization Therapy[J].Advances in Cardiovascular Diseases,2020,(9):268.[doi:10.16806/j.cnki.issn.1004-3934.2020.03.013]
[5]付辉,黄鹤.线粒体功能障碍在心血管疾病中的作用[J].心血管病学进展,2020,(3):306.[doi:10.16806/j.cnki.issn.1004-3934.2020.03.022]
FU Hui,HUANG He.Role of Mitochondrial Dysfunction in Cardiovascular Disease[J].Advances in Cardiovascular Diseases,2020,(9):306.[doi:10.16806/j.cnki.issn.1004-3934.2020.03.022]
[6]郭岐龙 芦颜美 张玲 张疆华 邢强 祖克拉·吐尔洪 李耀东 周贤惠 汤宝鹏.新疆地区老年慢性心力衰竭住院患者的病因、合并症及药物治疗的多中心回顾性分析[J].心血管病学进展,2020,(4):414.[doi:10.16806/j.cnki.issn.1004-3934.2020.04.021]
GUO Qilong,LU Yanmei,ZHANG Ling,et al.Etiology, Comorbidity and Drug Treatment of Elderly Inpatients with Chronic Heart Failure in Xinjiang: A Multi-center Retrospective Study[J].Advances in Cardiovascular Diseases,2020,(9):414.[doi:10.16806/j.cnki.issn.1004-3934.2020.04.021]
[7]毛玉琳 何胜虎.2型糖尿病和慢性心力衰竭[J].心血管病学进展,2020,(5):491.[doi:10.16806/j.cnki.issn.1004-3934.2020.05.012]
MAO Yulin,HE Shenghu.Type 2 Diabetes Mellitus and Chronic Heart Failure[J].Advances in Cardiovascular Diseases,2020,(9):491.[doi:10.16806/j.cnki.issn.1004-3934.2020.05.012]
[8]郭曦滢,孙煌,樊朝美,等.非奈利酮治疗慢性心力衰竭的研究进展[J].心血管病学进展,2020,(10):1021.[doi:10.16806/j.cnki.issn.1004-3934.2020.10.006]
GUO XiyingSUN HuangFAN ChaomeiZHANG Jian.Finerenone in the Treatment of Chronic Heart Failure[J].Advances in Cardiovascular Diseases,2020,(9):1021.[doi:10.16806/j.cnki.issn.1004-3934.2020.10.006]
[9]吴燕婷 李萍 吴寒.慢性心力衰竭再住院率研究进展[J].心血管病学进展,2021,(8):691.[doi:10.16806/j.cnki.issn.1004-3934-2021.08.005]
WU Yanting,LI Ping,WU Han.Rehospitalization Rate of Chronic Heart Failure[J].Advances in Cardiovascular Diseases,2021,(9):691.[doi:10.16806/j.cnki.issn.1004-3934-2021.08.005]
[10]李开 饶莉.线粒体自噬的分子生物学过程及其在心脏疾病中的作用[J].心血管病学进展,2022,(3):222.[doi:10.16806/j.cnki.issn.1004-3934.2022.03.000]
LI Kai,RAO Li.Molecular Biological Process of Mitophagy and Its Role in Heart Diseases[J].Advances in Cardiovascular Diseases,2022,(9):222.[doi:10.16806/j.cnki.issn.1004-3934.2022.03.000]